P-016 INCIDENCE AND MANAGEMENT OF RE-STENOSIS IN PATIENTS STENTED FOR INTRACRANIAL ATHEROSCLEROTIC DISEASE: A CONSECUTIVE SERIES OF 243 STENTED PATIENTS

M Alexander*, Z Barnard. Department of Neurosurgery, Cedars-Sinai Neurovascular Center, Los Angeles, CA

Introduction Angioplasty and stenting for intracranial atherosclerotic disease can re-establish adequate luminal diameter in highly stenotic arteries and improve cerebral blood flow. As in other vascular territories, intracranial stented arteries may develop delayed re-stenosis due to progression of atherosclerotic disease or endothelial hyperplasia. The primary strategies for management of re-stenosis have included aggressive medical therapy, angioplasty only, and repeat angioplasty and stenting.

Methods A total of 243 patients underwent intracranial angioplasty and stenting for symptomatic ICAD from 2000–2019 at two institutions. Patients were treated with balloon expandable coronary stents until 2002, when self-expanding intracranial nitinol stents became available. The series included: 21 balloon expandable coronary stents, 36 Neuroform or Atlas stents, 45 Enterprise stents, and 141 Wingspan stents. Of this group, 221 patients had delayed follow up intracranial vascular imaging at 6 months, 1 year, or longer. In follow up, 25 of the 221 patients (11.3%) developed significant re-stenosis, defined as 70% or greater. Eleven of the patients were symptomatic and 14 had no symptoms. A total of 17 patients underwent endovascular treatment of their re-stenosis, and 8 had medical management only.

Results The mean time interval for re-stenosis was 8.7 months. Of the 17 patients treated with endovascular therapy for re-stenosis, 4 patients had angioplasty only and 13 patients had angioplasty and stenting. There was one peri-procedural stroke in this group (5.9%) and no other strokes in the follow up period (mean 2.4 years, range 6 months – 7 years). Of the 8 patients who were managed medically, 1 patient had a stroke (12.5%) in the follow up period at 10 months (mean follow up 2.1 years, range 3 months – 5 years).

Discussion The preliminary data from this study suggests that patients with severe re-stenosis may be at significant risk of stroke, even if the re-stenosis is currently asymptomatic. As with other vascular territories, re-stenosis can be managed with multiple modalities, but repeat angioplasty and stenting in this series appears to be a low risk and viable option for these patients compared with medical therapy alone.

Disclosures M. Alexander: None.

P-017 TIME TO INTERVENTION IMPACTS OUTCOMES IN INTRACRANIAL STENTING: ANALYSIS OF 195 CONSECUTIVE PATIENTS IN THE WEAVE TRIAL AND WEAVE REGISTRY COHORTS

M Alexander*, 1J Chaloupka, 1A Zauner, 2B Baxter, 2W Yu. 1Department of Neurosurgery, Cedars-Sinai Neurovascular Center, Los Angeles, CA; 2Mt. Sinai Hospital, Miami, FL

Introduction The WEAVE Trial was a post-market surveillance study evaluating the peri-procedural stroke and death rate in 152 consecutive patients who were stented with the Wingspan stent under its current on-label FDA indication for symptomatic intracranial atherosclerotic stenosis (ICAS), eight days or longer after stroke. This trial demonstrated a 2.6% peri-procedural event rate at 72 hours. The WEAVE Registry was a companion registry for 46 consecutive patients stented in an off-label usage of the Wingspan stent at the same centers as the WEAVE Trial patients. The registry demonstrated a 23.4% peri-procedural event rate that was significantly higher than the on-label trial event rate (p < 0.0001).

Methods The peri-procedural event rate of stroke, symptomatic bleed, or death was recorded for all patients in the Trial and the Registry at 72 hours, and the clinical outcomes were verified by core study Neurologists. We evaluated potential risk factors of the stenting procedure to determine which elements were associated with a higher likelihood of peri-procedural complications, including time to stenting from last stroke, and other factors. A total of 195 patients were included in the analysis. The remaining three patients, in whom the qualifying events were not well documented, were excluded.

Results Six of 24 patients (25.0%) had events who were stented 0 to 7 days post-stroke, six of 69 patients (8.7%) had events who were stented 8 to 14 days post-stroke, and 3 of 102 patients (2.9%) had events who were stented 15 days or greater following their last stroke. Comparing the event rate in patients who were stented in the recommended time period of 8 days or longer after their last stroke (5.3%) to the event rate in patients who were stented early in the 0–7 day period (25.0%), there was a significant difference in clinical outcomes between the two groups (p = 0.0044). Other factors did not reach statistical significance independently.

Conclusions Early stenting of patients with symptomatic ICAS was the strongest predictor of poor outcome in the WEAVE Registry cohort. These results indicate that efforts should be made to temporize patients medically until day 8 or longer post-stroke to reduce the peri-procedural morbidity associated with intracranial stenting.

Disclosures M. Alexander: 2; C; Stryker Neurovascular. J. Chaloupka: 2; C; Stryker Neurovascular. A. Zauner: 2; C; Stryker Neurovascular. B. Baxter: 2; C; Stryker Neurovascular. W. Yu: 2; C; Stryker Neurovascular.

P-018 COST EFFECTIVENESS OF ENDOVASCULAR STROKE THERAPY. ANALYSIS FROM A COLOMBIAN HEALTHCARE PERSPECTIVE

1B Pabon*, 1J Tellez, 1J Arcos, 1P Gújarro, 1C Diaz. 1Neuroendovascular Surgery, Angioteam – Clínica del Norte, Medellin, Colombia; 2Angioteam, Medellin, Colombia; 3Neuroendovascular Surgery, Angioteam, Medellin, Colombia

Introduction To assess the cost-effectiveness of stent-retriever mechanical thrombectomy in combination with Intravenous Tissue Plasminogen Activator (IV-tPA) versus IV-tPA alone for the Treatment of Acute Ischaemic Stroke in Colombia.

Materials and methods Clinical data were taken from the SWIFT PRIME clinical trial. A lifetime Markov state transition model defined by the modified Rankin Scale score was developed to estimate costs and health outcomes (life years gained